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Chromosome aberrations, genomic instability, and
cancer predisposition are hallmarks of a number of syn-
dromes in which the defective genes recognize and/or
repair DNA damage or are involved in some aspect of
DNA processing. We report here direct interaction be-
tween BLM, mutated in Bloom’s Syndrome (BS), and
ATM, mutated is ataxia-telangiectasia, and we have
mapped the sites of interaction. Full-length BLM cDNA
corrected sister chromatid exchange (SCE) and radio-
sensitivity in BS cells. Mitotic phosphorylation of BLM
was partially dependent on ATM, and phosphorylation
sites on BLM were identified. A phosphospecific anti-
body against one of these sites (Thr-99) revealed radia-
tion-induced phosphorylation, which was defective in
ataxia-telangiectasia cells. Stable cell lines expressing
phosphorylation site mutants failed to correct radiosen-
sitivity in BS cells but corrected SCE. These mutants
also sensitized normal control cells to radiation and in-
creased radiation-induced chromosome aberrations but
did not cause SCE numbers to increase. These data sug-
gest that ATM and BLM function together in recognizing
abnormal DNA structures by direct interaction and that
these phosphorylation sites in BLM are important for
radiosensitivity status but not for SCE frequency.
Bloom’s syndrome (BS)1 is characterized by immunodefi-
ciency, infertility, telangiectatic erythema, growth retardation,
and chromosome aberrations, including gaps and rearrange-
ments and a predisposition to diabetes, leukemias, and lym-
phomas (1, 2). Some of these characteristics including chromo-
somal instability, immunodeficiency, and cancer predisposition
are shared with the genome instability syndromes ataxia-tel-
angiectasia (A-T), Nijmegen breakage syndrome (NBS), and
Fanconi anemia. Disturbances in DNA metabolism are evident
in BS including slow replication fork progression and abnormal
distribution of DNA replication intermediates (3, 4). BS cells
exhibit hypersensitivity to UV, hydroxyurea, and alkylating
agents (5) and a variable sensitivity to ionizing radiation (6).
The gene mutated in BS, BLM, encodes a 1417-amino acid
protein with homology to the RECQ family of helicases includ-
ing RECQL, Werner Syndrome protein, RECQ4 (mutated in
Rothmund-Thomson syndrome), RECQ5, and the yeast pro-
teins Sgslp and Rqh1p (2, 7–9). Overexpression of BLM and
purification from Saccharomyces cerevisiae showed that it had
ATP-dependent 3-5-DNA helicase activity (10, 11). BLM is a
nuclear protein present in nuclear bodies containing the pro-
myelocytic leukemia protein (12). It is also localized to diffuse
patches in the nucleolus and a subset of telomeres (11, 13). Its
localization to the nucleolus coincides with a peak of accumu-
lation in the S phase of the cell cycle (14). During mitosis, BLM
is post-translationally modified by phosphorylation followed by
a sharp decline in G1 phase. Immunodepletion of BLM from
Xenopus laevis extracts leads to inhibition of DNA replication
(15), and there is evidence that BLM acts to suppress double
strand breaks during replication (16). Although the exact role
of BLM remains undefined, it seems likely that it suppresses
inappropriate recombination.
The presence of BLM in a multiprotein complex BASC
(BRAC1-associated genome surveillance complex) with
BRCA1, ATM, several damage repair proteins, and the Mre11/
Rad50/Nbs1 complex suggests that it is functionally linked to
these proteins (17). Overlapping roles have already been de-
scribed for members of this complex. ATM is mutated in the
human genetic disorder A-T (18), Nbs1 is mutated in Nijmegen
breakage syndrome (19–21), and Mre11 is mutated in A-T-like
syndrome (22). Mutations in all three of these genes give rise to
a cellular radiosensitive phenotype, and there is evidence that
ATM and the Mre11/Rad50/Nbs1 complex function together in
recognizing damage in DNA (23–25). ATM is a member of the
phosphatidylinositol-3 kinase family of proteins that respond
to DNA damage by phosphorylating key substrates involved in
DNA repair and/or cell cycle control (26, 27). Activation of ATM
by double strand breaks in DNA leads to rapid phosphorylation
of p53 and Chk2 and subsequent activation of cell cycle check-
points (28–32). p53 is phosphorylated on serine 15 directly by
ATM and on serine 20 by Chk2 in an ATM-dependent manner
as part of the stabilization/activation of this molecule to ulti-
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mately bring about arrest of cells in G1 phase (31, 33). It has
also been demonstrated that ATM-dependent activation of
Chk2 requires Nbs1 (34). ATM phosphorylation of Nbs1 on
serine 343 is required for radiation-induced activation of the S
phase checkpoint, and mutations in either of these proteins
give rise to radioresistant DNA synthesis (23, 35). On the other
hand, BRCA1 function is required for both the S phase and
G2/M checkpoints with ATM phosphorylation of BRCA1 on
serine 1423 implicated in the G2/M checkpoint (36). Although it
is evident that ATM and BLM recognize abnormal structures
in DNA and suppress aberrant recombination, it is unclear as
to whether they overlap at the mechanistic level. In this report
we show that BLM interacts directly with ATM, BS cells
exhibit radiosensitivity, and that the mitotic hyperphospho-
rylation of BLM is partially ATM-dependent, and we identify
ATM-dependent phosphorylation sites on BLM that are phos-
phorylated post-irradiation in a dose-dependent manner.
Mutation of either of these two sites alters survival and chro-
mosome aberrations in response to radiation in transfected
control cells and fails to correct radiosensitivity in BS cells.
EXPERIMENTAL PROCEDURES
Cell Survival—Cells were plated at 106/ml in RPMI 1640 for 24 h
prior to incubation with CdCl2 (5 M) for 48 h prior to exposure to
ionizing radiation (0–4 grays). Cell viability was determined by adding
0.1 ml of 0.4% trypan blue to a 0.5-ml cell suspension. The number of
viable cells was determined at 72 h post-irradiation. The BS cell lines
HG1525, derived from 81(MaGrou), and HG2703, derived from
NR2(CrSpe), are from the Bloom’s Syndrome Registry.
Induced Chromosome Aberrations—Cells were irradiated with 1 gray
of -rays and incubated with Colcemid (0.1 g/ml) for 2 h prior to
harvesting. The cells were treated for 15 min in 0.075 M KCl, fixed in
methanol/glacial acetic acid, 3:1 (v/v), and spread on glass slides. The
cells were then stained with Giemsa, and 50 metaphases were analyzed
for each sample.
SCE Analysis—Differential staining of sister chromatids in met-
aphases was performed as described previously (2).
Fluorescence-activated Cell Sorter Analysis—Cell cycle distribution
after nocodazole was determined as described previously (35) using flow
cytometry with propidium iodide staining for DNA.
Expression and Purification of the GST-BLM Fragments—Four over-
lapping reverse transcription-PCR fragments with XhoI sites included
in the primers were generated to cover the entire BLM open reading
frame: BLM1 (1–1154), BLM2 (1070–2177), BLM3 (1978–3297), and
BLM4 (3246–4328). A detailed description of the constructs is available
from the authors upon request. These were cloned into the XhoI site of
the GST expression vector pGEX-4T-1. The GST clones were trans-
fected into BL21 cells, and expression was induced by the addition of 0.3
mM isopropyl-1-thio--D-galactopyranoside for 4 h. GST fusion proteins
were expressed, purified, and eluted with reduced glutathione (6 mg/
ml) as described previously (30). For ATM kinase analysis, GST-BLM 1,
2, 3, and 4 were thrombin-digested (1 unit, Amersham Biosciences) for
2 h at room temperature in phosphate-buffered saline and purified from
10% SDS-PAGE. The gel was reversibly stained with zinc, and the
appropriate band was excised, destained in 0.1 M EDTA/phosphate-
buffered saline, and eluted into elution buffer (0.05 M Hepes, pH 8, 0.1%
SDS, 0.5 mM EDTA, 5 mM DTT). The resulting protein was acetone-
precipitated and resuspended in H2O.
Antibody Production—The BLM-specific antibody, BLM1BA, was
raised against GST-BLM fusion proteins 1 and 4 purified from SDS-
PAGE and injected into sheep with Freund’s complete adjuvant. The
animal was given four booster shots at 4-week intervals, and the sheep
were bled 7 and 14 days after the third and fourth boost. The crude
antisera was tested against the preimmune sera for BLM specificity.
Antibody was purified using GST-BLM affinity chromatography. Phos-
phospecific antibody against Thr-99 BLM was generated by inoculation
of a phosphorylated peptide (KNAPAGQE Phospho-TQRGGSKSLC)
into rabbits (IMVS Adelaide). Antisera was purified by first passing
through a column containing non-phosphorylated peptide coupled to a
thiopropyl-Sepharose 6B gel and subsequently purified on a phos-
phopeptide-Sepharose column (Mimotopes, Melbourne, Australia).
Western Blotting, Immunoprecipitation, and Antibodies—Whole cell
extracts were made from control (C3ABR), A-T (AT1ABR, AT3ABR,
L3), and BS (HG1525, HG2703, GM 3403F) lymphoblastoid cell lines as
described previously. Briefly, cells were lysed in TGN buffer (50 mM
Tris-HCl (pH 7.4), 50 mM -glycerophosphate, 150 mM NaCl, 10% glyc-
erol, 1% Tween, 1 mM NaF, 1 mM sodium orthovanadate, 1 mM phen-
ylmethylsulfonyl fluoride, 2 g/ml pepstatin, 5 g/ml leupeptin, 10
g/ml aprotinin, 1 mM DTT) on ice for 30 min, cellular debris was
removed by centrifugation for 15 min at 4 °C, and protein concentration
was determined by the DC protein kit (Bio-Rad) as per the manufac-
turer’s instructions. For immunoblotting, 100 g was used. For co-
immunoprecipitation assays, 1 mg of each extract was precleared with
50 l of protein A/G-Sepharose 50% slurry and then immunoprecipi-
tated with 10 g of either ATM5BA or BLM1BA at 4 °C for 2–16 h. The
immune complex was purified by the addition of 50 l of protein A/G-
Sepharose and mixed for a further 2 h. The immune complexes were
washed five times with TGN, three times with TGN/0.2% Triton, and
two times with TGN/0.5% Triton, eluted into Laemmli buffer, and
separated on a 4.2% SDS-polyacrylamide gel, transferred to nitrocellu-
lose, and probed with either ATM5BA or BLM1BA. To synchronize the
cells in the M phase of the cell cycle, 0.4 M nocodazole was incubated
with exponentially growing cells for 16 h. Cells were released into fresh
RPMI 1640/10% fetal calf serum medium, and the cell cycle was fol-
lowed using fluorescence-activated cell sorter analysis. At 1 h post-
release, when the cells were determined to be in G2/M phase of the cell
cycle, whole cell extracts were prepared as described above, 100 g of
protein was loaded onto a 4.2% SDS-polyacrylamide gel, and the sample
was Western blotted for BLM. Antibodies used in this study were as
follows: ATM-2C1 (GeneTex), Phospho-p53 (Ser-15) (Cell Signaling
Technology), BRCA1 (Calbiochem), DNA-dependent protein kinase cat-
alytic subunit (DNA-PKcs) (Oncogene), nibrin (Novus), and actin
(Sigma).
Co-purification—ATM was cloned into pMEP4 and expressed in
AT3ABR as described previously (37). Cells were exposed to 5 M CdCl2
for 16 h, and whole cell lysates were prepared as described. The recom-
binant ATM protein was first purified on a HiTrap chelating column
(Amersham Biosciences), washed twice with TGN, and eluted with
increasing imidazole concentration (25, 50, 75, 100 mM) in TGN. Elu-
tions were prepared by boiling with Laemmli buffer and then separated
on a 4.2% SDS-polyacrylamide gel, transferred to nitrocellulose, and
probed with antibodies ATM5BA or BLM1BA.
GST Binding—12 overlapping GST-ATM constructs as described
previously (30) were used, as were the four BLM GST constructs. For in
vitro transcription/translation, full-length ATM was cloned into pBS, as
was the full-length BLM. Both BLM and ATM were translated in vitro
using the TnT-coupled transcription/translation kit (Promega). GST-
ATM fusion proteins (5 g) were incubated with in vitro transcribed and
translated [35S]methionine-labeled BLM protein in binding buffer (20
mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1% Nonidet
P-40) either with or without EtBr (50 g/ml) for 1 h at 4 °C, and then
washed in wash buffer (20 mM Tris, pH 7.4, 100 mM NaCl, 1 mM EDTA,
1 mM DTT, 0.25% Nonidet P-40, 10% glycerol). GST-BLM fusion pro-
teins (5 g) were incubated with in vitro transcribed and translated
35S-labeled ATM protein in binding buffer with EtBr for 1 h at 4 °C and
then washed in wash buffer as described. The bound proteins were
analyzed by SDS-PAGE followed by fluorography.
In Vitro Mutagenesis—Two site-directed mutations were generated
in the BLM GST-1 fragment. Both Thr-99 and Thr-122 were mutated by
the QuikChange site-directed mutagenesis kit (Stratagene) as per the
manufacturer’s instructions.
Primer 1 (5-AGCAGGACAGAAGCACAGAGAGGTGGATC-3) and
Primer 2 (5-TCGTCCTGTCTTCGTGTCTCTCCACCTAG-3) were used
to mutate Thr-99. Accordingly, Primer 3 (5-GAAGTTGTATGCATGC-
CCAAAACACACCA-3) and Primer 4 (5-CTTCAACATACGTGACGG-
GTTTTGTGTGGT-3) were used to mutate Thr-122.
ATM Kinase Assay—ATM kinase assays were performed as de-
scribed previously (29). Briefly, 1 mg of whole cell extract was pre-
cleared for 30 min with rotation at 4 °C with 50 l of a 50% v/v slurry
of protein A/G-Sepharose. 2 l of ATM5BA crude serum was added, and
the complex was rotated for a further 2 h, and then the complex was
removed by addition of 50 l for the protein A/G-Sepharose mix and
rocked for another hour. The complex was washed three times with
TGN, once with 0.5 M LiCl, 100 mM Tris-HCl (pH 7.4), and twice with
kinase buffer (10 mM Hepes (pH 7.5), 50 mM -glycerophosphate, 50 mM
NaCl, 10 mM MgCl2, 10 mM MnCl2, 5 M ATP, 1 mM DTT). Half of this
reaction was removed and run on a 4.2% polyacrylamide gel and West-
ern blotted for the amount of ATM present in the immunoprecipitation.
The remaining pellet was resuspended in 20 l of kinase buffer with the
addition of 1 g of substrate and 10 Ci of [-32P]ATP and incubated at
30 °C for 30 min followed by the addition of 5 l of 5 Laemmli buffer
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(5% SDS, Tris-HCl (pH 6.8), -mercaptoethanol, bromphenol blue),
heated to 95 °C for 5 min, and run on a 10% polyacrylamide gel. The
resulting gel was stained with bromphenol blue to check the loading of
the substrate followed by autoradiography.
RESULTS
BLM Interacts Directly with ATM—The phenotype observed
in BS suggests that BLM plays a role in recognizing abnormal
structures in DNA and suppressing recombinational events
that lead to genomic instability. To understand more fully the
role of BLM in maintaining genomic stability, we initially em-
ployed the yeast two-hybrid system to identify proteins that
interact with and influence the function of BLM. Full-length
BLM cDNA was divided into two overlapping fragments and
was PCR-cloned into the yeast-pA22 vector containing the Gal4
FIG. 1. BLM interacts directly with ATM. A, whole cell extracts (5 mg) from control (C3ABR) and A-T (L3) cells were immunoprecipitated
(IP) with antibodies against ATM (ATM5BA), BLM, or nonspecific antibody followed by immunoblotting (IB) for ATM and BLM (upper panel).
Immunoblotting was also carried out with extracts prepared from the C3ABR, L3, and 2 BS cell lines (HG1525, HG2703) for ATM and BLM.
Loading was determined using an antibody to DNA-PK. B, use of nickel chelate chromatography to demonstrate binding of ATM and BLM.
AT3ABR cells stably transfected with full-length hexahistidine-tagged ATM cDNA (pMAT1) were induced to express ATM with CdCl2 prior to
application to a nickel chelate column. Bound protein was eluted with imidazole. Lanes 1–4 and lanes 5–8 represent 25, 50, 75, and 100 mM
imidazole elutions. Eluted samples were separated on a 4.2% SDS-PAGE and immunoblotted with ATM5BA and BLM1BA antibodies. C, BLM
binding to GST-ATM fusion proteins. In vitro transcription/translated [35S]methionine-labeled BLM was incubated with 5 g of ATM GST fusion
proteins covering the length of ATM (30). Binding was determined on 4.2% SDS-PAGE followed by fluorography. BLM input lanes represent 10%
of the label used in binding. Amounts shown for ATM GST input are those used in the binding. D, fine mapping of BLM binding to GST-ATM1.
Numbers represent nucleotides of ATM from the N terminus, and 5X represents pGEX only. AA, amino acids. E, ATM binding to GST-BLM fusion
proteins. As described for panel C, ATM was labeled with [35S]methionine prior to binding to BLM GST fragments 1–4 from the N-terminal end.
ATM and BLM Functional Interaction 30517
 at UQ Library on October 16, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
DNA-binding domain, pGBT9-R1 (nucleotides 1998–4328) and
pGBT9-A8 (nucleotides 72–2084). pGBT9-A8 was found to self-
activate and was thus discarded. Following sequential trans-
formation of the yeast strain Y190 with pGBT9-R1 and a cDNA
library (human leukemia matchmaker DNA library) fused with
the Gal4 activation domain vector pG6AD10, 3 106 independ-
ent clones were screened on leu trp his plates in the pres-
ence of 3-amino-1,2,4-triazole, and the resultant colonies were
further screened using the -galactosidase filter assay leading
to the identification of five positive clones. Sequence analysis of
two strongly positive clones (3F3 and 3C5) identified a 5.5-kb
fragment from the C terminus of ATM (ataxia-telangiectasia-
mutated) cDNA (3F3) and BLM cDNA (3C5). Self-interaction is
in keeping with results showing that BLM forms hexameric
ring structures (38).
To confirm the interaction of BLM with ATM, we employed
co-immunoprecipitation and co-purification on nickel chelate
chromatography. When extracts from control cells (C3ABR)
were immunoprecipitated with ATM5BA antibody and immu-
noblotted with anti-BLM antibody, BLM was shown to associ-
ate with ATM (Fig. 1A, upper panel). As expected, similar
immunoprecipitates from the A-T cell line L3, which does not
express ATM (39), showed no evidence of co-immunoprecipita-
tion nor did a control antibody immunoprecipitate BLM (Fig.
1A, upper panel). Immunoblots reveal the relative amounts of
ATM and BLM proteins in the different cell lines (Fig. 1A,
lower panel). Reciprocal experiments were carried out using
anti-BLM antibody, but this failed to show evidence of associ-
ation, presumably because the antibody recognition site inter-
fered with the ATM/BLM interaction. Consequently we used an
alternative approach to look for association in AT3ABR cells
expressing ATM containing a hexahistidine sequence (pMAT1).
These cells were stably transfected with ATM cDNA and in-
duced with CdCl2 to express ATM as described previously (37).
Extracts were applied to a nickel chelate resin, and ATM was
eluted with imidazole, run on an SDS-polyacrylamide gel, and
immunoblotted with anti-ATM and BLM antibodies. Again as
observed with co-immunoprecipitation, there was evidence for
the association of ATM and BLM (Fig. 1B, lanes 1–4) with BLM
preferentially eluted in the same elution fraction as ATM after
CdC12 induction of the ATM levels. There was no evidence of
ATM/BLM interaction in the absence of induction (Fig. 1B,
lanes 5–8). The background levels of BLM in the uninduced
samples (lanes 5–8) are due to some nonspecific binding of
BLM to the nickel chelate column.
To map the regions of interaction, we used a series of 12
GST-ATM fusion proteins representing the complete ATM pro-
tein (30). Binding was determined with 35S-labeled in vitro
transcribed and translated full-length BLM in the presence
and absence of ethidium bromide to minimize the likelihood of
interaction through DNA. BLM bound to GST-ATM-1 (amino
acid residues 1–257), GST-ATM-10 (residues 2427–2641), and
GST-ATM-12 (residues 2682–3012) in reactions without
ethidium bromide (Fig. 1C). However, when this compound was
included, GST-ATM-1 and GST-ATM-12 were found to bind
equally well to BLM, but there was reduced interaction with
GST-ATM-10 (results not shown). Binding of BLM to GST-
ATM-10–12, which contains the kinase domain of ATM, is
consistent with this protein being a substrate for ATM kinase.
The binding of BLM to GST-ATM-1 was strongest (50% of the
input). To map in more detail the region of interaction on
ATM-1, we prepared a number of small overlapping GST fusion
proteins within this area. Binding studies with 35S-labeled
BLM revealed that the smallest region of overlap was a se-
quence of 24 nucleotides, which corresponds to amino acids
82–89 (Fig. 1D). It is of some interest that the strongest bind-
ing site on ATM for p53 and BRCA1 also maps to this region
(30, 40). Mapping the region of interaction in BLM was carried
out using four overlapping GST fusions (GST 1–4, numbered
from the N-terminal end). Binding of GST-BLM-3 amino acid
residues 636–1074 to 35S-labeled full-length ATM was ob-
served (Fig. 1E). Addition of ethidium bromide did not alter
this pattern of binding (results not shown).
Correction of SCE and Radiosensitivity in BS Cells—A major
characteristic of A-T cells is extreme sensitivity to ionizing
FIG. 2. Correction of radiosensitivity in BS cells. A, cell survival
at day 3 after irradiation as determined by trypan blue exclusion.
C3ABR, control; L3, A-T; HG1525 and HG2703, BS. Vector only trans-
fected BS cells, HG1525/pMEP4, and BS cells transfected with full-
length BLM cDNA, HG1525/BLM. Gy, grays. B, stably transfected BS
cells with either vector only (HG1525/pMEP4) or full-length BLM
(HG15245/BLM) were incubated with CdCl2 (), and extracts were
prepared 48 h later. Extracts were immunoblotted (IB) with either BLM
antibody or ATM5BA.
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radiation (41). Since we had shown that BLM and ATM inter-
act, it was possible that this interaction might influence the
radiation response and that loss of BLM in BS cells might
exacerbate this response. It is clear from the results in Fig. 2A
that HG1525 and HG2703 cells are intermediate between con-
trol and A-T cells in radiosensitivity. These two cell lines are
characteristic of BS cells with elevated SCE in the unirradiated
state, HG1525 (75.7 SCE/46 chromosomes) and HG2703 (82.5
SCE/46 chromosomes) as compared with three to seven in
controls (Table I). To test the specificity of these observations,
we stably transfected BS cells with an Epstein-Barr virus-
based vector expressing full-length BLM under the control of
an inducible metallothionein promoter (HG1525/BLM). Incu-
bation of transfected cells with CdCl2 led to an induction of
BLM to a level comparable with that expressed in control cells
(Fig. 2B). This level of expression enhanced the radioresistance
of BS cells to that in controls (Fig. 2A). Radiation-induced
chromosome aberrations in BS cells were also reduced after
transfection with full-length BLM cDNA from 2.0 to 1.35 in-
duced chromosome aberrations/metaphase (Table II). The in-
duced chromosome aberration value for controls is 0.92  0.11,
whereas that for A-T is 3.03  0.09.
Mitosis-associated Phosphorylation of BLM Is ATM-depend-
ent, and ATM Phosphorylates BLM at Two Sites—Since BLM is
hyperphosphorylated in mitosis (14), we determined whether
this phosphorylation was ATM-dependent and what sites were
involved. Cells were blocked in G2/M with the microtubule-
stabilizing agent, nocodazole, released and harvested 1 h later,
and immunoblotting for BLM was carried out. The results in
Fig. 3 demonstrate that the majority of BLM exists in a hyper-
phosphorylated form (retarded species) for control cells at 1 h
after release from nocodazole (69% G2/M cells). The ratio of
phosphorylated to unphosphorylated BLM was 3 for the con-
trol cell line and 2 for a second control (results not shown). On
the other hand, in three A-T cell lines examined, the greatest
proportion of BLM was in the hypophosphorylated form at 1 h
after release with the ratio of the two forms ranging from 0.2 to
0.8 (65–73% G2/M cells). Since we showed that BLM interacts
directly with ATM, we determined whether BLM was a sub-
strate for ATM kinase. To address this, we employed the four
overlapping GST-BLM fusion proteins (described above) as
substrates for immunoprecipitated ATM. The results in Fig.
4A, upper panel, demonstrate that only the GST-BLM-1 (N-
terminal) fragment is phosphorylated by ATM kinase. When
immunoprecipitates from an A-T cell line, L3, were used, no
kinase activity was observed (Fig. 4A, lower panel). Based on
consensus sequences described by Kim et al. (42), two potential
phosphorylation sites (TQ 99–101; TQ 122–123) were identi-
fied in the BLM N-terminal peptide for ATM kinase (Fig. 4B).
A chromatographically purified N-terminal fragment of BLM
(amino acids 1–200) was also efficiently phosphorylated by
ATM (Fig. 4C). Mutation of Thr-99 to glycine resulted in a
significant reduction in phosphorylation of the thrombin-
cleaved GST fusion protein by ATM, indicating that this was a
major site for ATM kinase in vitro. Residual phosphorylation
suggests that Thr-122 is also phosphorylated to a lesser extent.
When cells were exposed to radiation, there was an enhance-
ment of ATM kinase activity over a 2-h incubation period using
TABLE II
Correction of radiation-ICA
Control (C3ABR) and BS (HG1525) cells were stably transfected as indicated, and ICA/metaphase, was determined. sb, chromatid breaks, cb,
chromosome breaks; Int, interchanges, N, the number of metaphases scored. Transfected cells are the same as described in Table I legend. The ICA
values for control and A-T cells over a series of seven independent experiments are 0.92  0.11 (C3ABR) and 3.03  0.09 (A-T, L3). CI, confidence
interval.
Cell line sb cb Int N ICA/metaphase Standarderror
Lower 95% CI
for mean
Upper 95% CI
for mean
P value
(Wilcoxon test)
C3ABR 43 2 1 49 0.94
C3ABRpMEP4 46 0 0 50 0.92
C3ABRBLM 42 0 0 50 0.84
C3ABRThr-99(A)a 102 0 1 50 2.10 0.25 1.59 2.61 0.017
C3ABRThr122(A)a 86 1 0 50 1.74 0.20 1.34 2.14 0.024
C3ABRThr99/122(A)a 82 0 1 50 1.66 0.25 1.16 2.16 0.026
HG1525 110 2 3 50 2.30 0.28 1.73 2.87
HG1525pMEP4b 125 0 1 50 2.52 0.29 1.93 3.11 0.624
HG1525BLMb 67 1 1 51 1.35 0.22 0.92 1.79 0.012
L3 152 0 1 50 3.06
a Compared with C3ABR.
b Compared with HG1525.
TABLE I
SCE and correction in transfected cells
Control (C3ABR) and BS (HG1525) cells were stably transfected as indicated, and SCE/metaphase was determined after induction with CdCl2.
P values for HG1525 transfected cells represent a comparison with SCEs in the parental untransfected line (HG1525). Values are not provided for
C3ABR transfected cells, but they are all significantly lower than BS cells. pMEP4 is the empty vector, BLM is wild type BLM in the vector, and
Thr-99(A) and Thr-122(A) represent mutant forms of BLM. N is the number of metaphases scored. L3 is an A-T cell line. CI, confidence interval.
Cell line N SCEmetaphase
Standard
error
Lower 95% CI
for mean
Upper 95% CI
for mean
P value
(Wilcoxon test)
C3ABR 10 6.80 0.36 5.99 7.61
C3ABRpMEP4 10 2.90 0.28 2.27 3.53
C3ABRBLM 8 3.88 0.48 2.74 5.01
C3ABRThr-99(A) 12 2.69 0.26 2.12 3.26
C3ABRThr-122(A) 20 3.40 0.27 2.84 3.96
C3ABRThr-99/122 12 7.58 1.01 5.36 9.81
HG1525 10 75.70 6.27 61.52 89.88
HG1525pMEP4 12 63.08 4.71 52.72 73.44
HG1525BLM 19 12.32 1.42 9.33 15.30 0.0001
HG1525Thr-99(A) 20 17.65 3.04 11.30 24.00 0.0001
HG1525Thr-122(A) 17 26.82 3.60 19.19 34.45 0.0001
L3 8 9.5
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the GST-BLM fragment as substrate (Fig. 4D). However, as
expected, when a fragment with mutated Thr-99 was em-
ployed, radiation did not lead to phosphorylation. Yet when
Thr-122 was mutated, reduced phosphorylation was still evi-
dent (Fig. 4D). Under these conditions, increased phosphoryl-
ation of the p531–44 fragment was observed. Comparable levels
of ATM protein were demonstrated by immunoblotting the
immunoprecipitated material. The specificity of this phospho-
rylation was confirmed using immunoprecipitated ATM from
an A-T mutant (AT1ABR) that failed to phosphorylate BLM
above basal levels. It is of interest that the basal level of ATM
kinase is elevated in the BS cell line (HG2703) and decreases
initially in response to radiation (Fig. 4D).
Functional Significance of Phosphorylation Sites—Since
ATM was capable of phosphorylating BLM on Thr-99 most
efficiently in vitro, we prepared a phosphospecific antibody
against this site to determine its functional significance. BLM
was immunoprecipitated from extracts of control cells with or
without radiation exposures prior to immunoblotting with anti-
BLM antibody. The results in Fig. 5 demonstrate a low basal
level of phosphorylation on Thr-99 of BLM, which increased
with increasing radiation dose. It is evident that this is ATM-
dependent since the response is much reduced in A-T cells (Fig.
5). Immunoprecipitation with anti-BLM antibody showed nor-
mal levels of BLM in control and A-T cells. There is an indica-
tion that BLM protein decreases in amount with high radiation
dose in A-T cells, but this does not account for failure to observe
BLM phosphorylation. As a further test of functional signifi-
cance, we employed Thr-99 and Thr-122 mutant forms to es-
tablish stable cell lines. Expression of either the Thr-99 or
Thr-122 mutants in BS cells failed to correct radiosensitivity,
whereas normal full-length BLM cDNA restored survival to
normal levels (Fig. 6A). However, as for full-length BLM, both
mutants reduced SCE levels to those observed in control cells,
providing evidence for a dissociation of SCE and DNA damage-
induced aberrations. When introduced into control cells, full-
length BLM did not alter the phenotype, but the Thr-99 and
Thr-122 mutants sensitized these cells to radiation to an extent
intermediate between control and A-T (Fig. 6B) and caused a
significant elevation in the number of radiation-induced chro-
mosome aberrations (Table II). The double mutant also led to
increased aberrations. However, none of the mutants increased
FIG. 3. Mitotic phosphorylation of BLM is ATM-dependent.
Cells were synchronized using the microtubule inhibitor nocodazole (0.4
M) for 16 h and then released into fresh medium for 1 h prior to
harvesting. Extracts were immunoblotted for BLM/ATM and DNA-
PKcs as a loading control on a 4.2% SDS-PAGE gel. The ratio of
phosphorylated (upper band) to unphosphorylated (lower band) was
determined using a PhosphorImager. The percentage of cells in the
G2/M phase of the cell cycle is shown.
FIG. 4. BLM is a substrate for ATM kinase. A, phosphorylation of GST-BLM fusion proteins. ATM was immunoprecipitated from control
extracts, and ATM kinase activity was determined using the GST-BLM fusion proteins 1–4 and p531–44 (upper panel). Immunoprecipitates were
also prepared from A-T (L3) cell extracts using the same substrates to determine ATM kinase activity (lower panel, overexpressed). B, mutation
of the two potential ATM kinase sites in GST-BLM1 site 1. 98-ETQR-101 was mutated to EAQR by mutating nucleotide 369 (an A to a G). In site
2, 121-TTQN-124 was mutated to TAQN by mutating nucleotide 437 (an A to a G). C, ATM kinase activity with BLM and mutated fragments.
BLM1, GST-BLM1 (N-terminal fragment); Thr-99 T3A, Thr-99 Thr 3 Ala within BLM1; Thr-122 T3A, Thr-122 Thr 3 Ala within BLM1 and
a purified N-terminal peptide, amino acids 1–200 (BLM 1–200). D, radiation-induced phosphorylation of BLM1 fragments. Extracts were prepared
from C3ABR, HG2703, and AT1ABR cells at 0, 1, and 2 h post-irradiation (10 grays), and ATM kinase activity was determined. Activity was also
determined using the two mutated fragments (Thr-99 Thr3 Ala and Thr-122 Thr3 Ala) and p531–40. Loading was determined by immunoblotting
of immunoprecipitated ATM.
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SCE levels (Table I), again supporting a separation of SCE and
chromosome aberration effects.
DISCUSSION
We have provided evidence for a functional relationship be-
tween the products of two genes that, when mutated, give rise
to the human disorders (A-T and BS) characterized by genome
instability, immunodeficiency, and cancer predisposition (2,
41). Although these are distinct diseases, the BLM/ATM inter-
action is intriguing since it adds to the list of syndromes fea-
turing genome instability and cancer predisposition whose
gene products overlap functionally. Extensive overlap exists in
the phenotypes of A-T and NBS, and recent data demonstrate
that Nbs1 is phosphorylated by ATM and that this modification
is essential for the cellular response to DNA damage (23–25,
43, 44). Mutations in Mre11, part of the complex with Nbs1,
give rise to an A-T-like syndrome featuring radiosensitivity,
radioresistant DNA synthesis, and chromosome fragility (22).
These data reveal that ATM and the Mre11/Rad50/Nbs1 com-
plex operate in the same DNA damage response pathway(s)
and give rise to three syndromes in the chromosomal breakage
category. A new interaction, BLM with ATM, is now included in
this list and adds another dimension of complexity to the rec-
ognition of abnormal structures in DNA during aberrant rep-
lication and/or in response to DNA damage. As observed with a
number of other substrates, interaction of BLM with ATM is
complex, occurring with the kinase domain and the N terminus
of ATM. The interaction with the N terminus region of ATM
was narrowed to a minimal region of 8 amino acids (VSAS-
TQAS, 82–89). This sequence also corresponds to the minimal
region for p53 and BRCA1 binding (30, 40).2 Since this region
of ATM bound most strongly to BLM and since the helicase
domain of BLM bound ATM tightly, it is possible that these
regions interact, allowing ATM to bind and phosphorylate
Thr-99 and Thr-122 at the N terminus of BLM. More detailed
mapping of these interactions sites requires further studies.
The results described here reveal that ATM interacts with and
directly phosphorylates BLM on Thr-99 and Thr-122 near the
N terminus of the protein. These phosphorylations are physio-
logically significant since expression of mutant forms fails to
correct radiation-induced damage in BS cells and enhanced
radiosensitivity and chromosome aberrations in control cells.
What is intriguing about these mutations of BLM is that they
do not predispose to elevated SCE. In essence, we have dem-
onstrated that specific mutations near the N terminus of BLM
render the cells susceptible to radiation damage at least in part
by interference with the function of ATM kinase and that this
is separate from the helicase activity of BLM which is required
for the prevention of SCE (2). Thus it appears that BLM is
involved in maintaining genome stability in different path-
ways, one of which is ATM-dependent. The dominant interfer-
ing effect of the BLM mutants in normal cells can be explained
by mutant protein interacting with BLM partner proteins crit-
ical for maintaining DNA integrity. The BASC complex, which
contains several proteins involved in maintaining genome sta-
bility, represents one such target (17). Some of the heterogene-
2 H. Beamish, P. Kedar, H. Kaneko, P. Chen, T. Fukao, C. Peng,
S. Beresten, N. Gueven, D. Purdie, S. Lees-Miller, N. Ellis, N. Kondo,
and M. F. Lavin, unpublished data.
FIG. 5. Radiation-induced phosphorylation of BLM on Thr-99
is ATM-dependent. Upper lane, extracts from unirradiated and irra-
diated C3ABR and AT1ABR cells were immunoprecipitated with an
antibody specific for Thr-99 phosphorylated BLM. Protein was sepa-
rated on 6% SDS-PAGE and immunoblotted with anti-BLM antibody.
Lower lane, immunoprecipitation of BLM from C3ABR and ATIABR
extracts with anti-BLM antibody followed by immunoblotting with the
same antibody. Gy, grays.
FIG. 6. Effect of phosphorylation site mutants of BLM on radiation-induced cell survival in transfected BS and control cells. A, cell
survival in HG1525 cells transfected with BLM constructs. The BS line HG1525 was transfected with full-length BLM cDNA or the Thr-99 and
Thr-122 mutants, and stable cell lines were established. Cell survival was determined at day 3 after irradiation by trypan blue exclusion. C3ABR
(normal) and L3, an A-T cell line, were used as controls. Gy, grays. B, cell survival in C3ABR cells transfected with BLM constructs. The control
cell line C3ABR was transfected with full-length BLM cDNA or the Thr-99 and Thr-122 mutant forms, and stable cell lines were established. Cells
were irradiated and survival determined.
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ity observed in BS patients might be explained by the presence
of mutant protein. However, more than 90% of patients have
mutations predicted to give rise to truncated protein, which is
highly unstable and unlikely to cause interference with other
functions. We have also demonstrated that radiation enhances
the amount of Thr-99 phosphorylated BLM with increasing
doses. Furthermore, this increase was defective in A-T cells,
implicating ATM in this process. Thus in addition to phospho-
rylating BLM in vitro, ATM is also responsible for radiation-
induced phosphorylation in vivo. It is not clear whether this is
direct or mediated through another kinase, but based on our
observations that these two proteins interact, it points to BLM
being a substrate for ATM in response to DNA damage, joining
an ever growing list of other substrates (45). Ababou et al. (46)
have shown previously that BLM is retarded in its migration
on SDS-PAGE in response to radiation and that phosphatase
treatment restored migration to normal, providing evidence for
radiation-induced phosphorylation. They also demonstrated
that this shift was ATM-dependent but did not identify the site
of phosphorylation. In addition to the radiation-induced phos-
phorylation of BLM, Ababou et al. (46) observed an increase in
BLM protein at 8 and 24 h post-irradiation. This differs from
other results in which BLM is rapidly degraded in cells under-
going DNA damage-induced apoptosis (47), and we saw some
evidence of this in A-T cells (Fig. 5). It is also noteworthy that
the basal level of ATM kinase activity is elevated in the BS cell
line HG2703 (Fig. 4D). This is also the case for two other BS
cell lines (results not shown) and may be explained by the
inherent genomic instability of these cells. This explanation is
supported by recent observations that 84% of undamaged BS
cells contained Rad51 foci (48). Since these foci normally occur
in response to radiation-induced double strand breaks in DNA,
it seems likely that BS cells contain constitutively high levels of
DNA breaks responsible for activation of ATM kinase. What is
more difficult to explain is the reduction in ATM kinase at
short times after irradiation in BS cells (Fig. 4D), which sug-
gests that BLM may have a modulating role on ATM kinase.
Recent data reveal that BLM is required for correct relocal-
ization of the Mre11/Rad50/nibrin complex at sites of stalled
replication forks after treatment with hydroxyurea (49). Fur-
thermore, ATR phosphorylates BLM, and this is positively
correlated with the accurate subnuclear relocalization of the
Mre11/Rad50/nibrin complex after hydroxyurea treatment. In
the model proposed, BLM associates with stalled replication
forks and assists in the loading of the Mre11/Rad50/nibrin
complex. Phosphorylation of BLM by ATR facilitates recogni-
tion of the lesion, eventually leading to resolution of the stalled
replication fork. Since relocalization of the complex reaches a
maximum by 8 h, the timing involved raises the issue of the
importance of this complex formation as a primary event in
resolving the blocked fork. Hyperphosphorylation of BLM dur-
ing mitosis is at least partially dependent upon ATM, and it is
of interest as to whether ATR also plays a role in this process.
The functional interaction between ATM and BLM during S
phase in response to abnormal DNA structures and in mitosis,
as well as the possible overlap in sites of phosphorylation for
these different processes, requires further investigation. The
presence of ATM, ATR, and BLM in complexes together with
DNA damage recognition and repair proteins provides a vehicle
for the functional coordination of these activities for the main-
tenance of genome integrity.
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